


[Site Map](#) NEW! - [Finance Home](#) - [Yahoo!](#) - [Help](#)


**'BEAT THE NUMBERS'**

**click here**

**YAHOO! Finance**  
Real-Time Package

Crush the market with streaming quotes & news.

[ [Latest Headlines](#) | [Market Overview](#) | [News Alerts](#) ]

**Friday November 2, 7:30 am Eastern Time**

### Press Release

SOURCE: *Pharmacyclics, Inc.*

#### Related Quote

PCYC	9.13	-0.04
delayed 20 mins - <a href="#">disclaimer</a>		
Quote Data provided by Reuters		
<a href="#">Get Quotes</a>		

## Pharmacyclics Announces Six Xcytrin Abstracts to Be Presented at ASTRO Annual Meeting Next Week

SUNNYVALE, Calif., Nov. 2 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: [PCYC](#) - news) announced today that six abstracts related to its lead investigational product candidate, Xcytrin® (motexafin gadolinium) Injection, are being presented next week at the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) at the Moscone Center in San Francisco.

Among the highlights is an oral presentation on Wed., Nov. 7, that will review baseline data in patients enrolled in the company's pivotal 429-patient Phase III clinical trial of Xcytrin for the potential treatment of brain metastases. That study will report on the strong correlation between tumor size and neurocognitive function, further validating one of the study's two co-primary endpoints. Other studies will highlight Xcytrin's potential utility in glioblastoma multiforme (i.e., GBM or primary brain tumors) and further elucidate Xcytrin's unique mechanism of action.

"We have some very important data on Xcytrin being presented at ASTRO this year in advance of announcing top-line results of our pivotal Phase III trial in mid- to late-December," said Richard A. Miller, M.D., Pharmacyclics' president and chief executive officer.

The six abstracts, which are available upon request or can be downloaded at [www.astro.org](http://www.astro.org), are:

1. Abstract #242: Impairment of Neurocognitive Function in Brain Metastases Patients: Baseline Results from the Phase III Trial with Motexafin Gadolinium (Oral Presentation by Dr. Minesh Mehta, University of Wisconsin-Madison Medical School, on Wed., Nov. 7 at 11:25 a.m. PST, Room 235);
2. Abstract #1059: A Phase I Dose Escalation Trial of Motexafin Gadolinium (Gadolinium Texaphyrin, Xcytrin(R)) as a Radiation Sensitizer in Newly Diagnosed Glioblastoma Multiforme (Poster Presentation by Dr. Judith Ford, UCLA Medical Center, on Tues., Nov. 6 at 2:15 p.m. PST, Room 105-106);
3. Abstract #2349: Most Troublesome Quality of Life Concerns in Patients with Brain Metastases: Baseline Results from the Phase III Trial with

- Motexafin Gadolinium (Poster Presentation by Dr. Patrick Rodrigus, Verbeeten Institute, Netherlands, on Nov. 4 & 5, Room 105-106);
- 4. Abstract #2016: Redox Cycling of Texaphyrins in the Presence of Reducing Metabolites: The Importance of the Metal Cation (Poster Presentation by Dr. Darren Magda of Pharmacyclics, on Nov. 4 & 5, Room 105-106);
- 5. Abstract #2007: Motexafin Gadolinium Enhances Radiation Response in Hypoxic and Norm-Oxic Murine Mammary Carcinoma (Poster Presentation by Dr. Jason Koutcher, Memorial Sloan-Kettering Cancer Center, on Nov. 4 & 5, Room 105-106);
- 6. Abstract #2048: Brain Metastases Regress Isometrically Following Radiation, Thereby Allowing the Use of 1D W.H.O. Recist Criteria for Adequate Response Evaluation (Poster presentation by Dr. Afshin Forouzannia, University of Wisconsin, Madison, on Nov. 6 & 7, Room 105-106).

### About Xcytrin

Xcytrin, the first of a new class of drugs called texaphyrins, selectively accumulates in cancer cells and disrupts cellular metabolism by a unique mechanism of action. By interfering with the flow of energy in cancer cells, Xcytrin makes the tumor potentially more responsive to the effects of radiation and chemotherapy without increasing damage to normal tissue.

### About Brain Metastases and Primary Brain Tumors

Brain metastases is one of the most common conditions treated with radiation therapy. There are about 170,000 cases per year and the incidence is increasing. The most common causes of brain metastases are lung and breast cancer. Brain metastases occur when cancer cells spread to the brain and grow, causing major neurologic complications and, in most cases, death. Patients with brain metastases usually suffer serious deterioration of neurocognitive function such as loss of short-term memory, compromised verbal skills and fine motor coordination, and reduction in cognitive performance. Most patients with brain metastases have multiple lesions and are not candidates for surgical resection or radiosurgery. The goal of whole brain radiation therapy is to reverse or prevent neurological deterioration and prevent death due to tumor progression in the brain.

There are about 17,000 new cases of primary brain and nervous system tumors each year in the U.S. and more than 13,000 deaths occur from these types of malignancies.

Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis and retinal disease. The company's products are rationally designed, ring-shaped small molecules called texaphyrins that disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. When activated by various forms of energy, including X-ray and light, these texaphyrins can help to reduce or eliminate the diseased tissue. More information about the company, its technology, and products can be found on its web site at [www.pcyc.com](http://www.pcyc.com).

Note: The statements made in this press release about progress and reports of clinical trial results and product development activities, other than statements of historical fact, are forward-looking statements. The forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements, including risks associated with the initiation, timing, and results of clinical trials, the progress of research and development programs, the

regulatory approval process in the U.S. and other countries, and future capital requirements. For further information about risks that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to, its reports on Form 10-Q and 10-K. Pharmacyclics®, Xcytrin®, and the "pentadentate" logo are registered trademarks of Pharmacyclics, Inc.

*SOURCE: Pharmacyclics, Inc.*

[Email this story](#) - [Most-emailed articles](#) - [Most-viewed articles](#)

---

**More Quotes and News:** Pharmacyclics Inc (NasdaqNM:[PCYC](#) - news)

**Related News Categories:** [biotech](#), [medical/pharmaceutical](#)

---

[Search News](#)

[Help](#)

---

Copyright © 2001 Yahoo! Inc. All rights reserved. [Privacy Policy](#) - [Terms of Service](#)

Copyright © 2001 [PR Newswire](#). All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

[Questions or Comments?](#)